Early methylene blue for reducing organ dysfunction in severe burn patients

Phase 4, randomised, open-label trial of methylene blue in burn injury, burn shock and multiple organ dysfunction syndrome (MODS) (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Incidence of new-onset or worsening organ dysfunction between randomization and 7 days after burns. Planned start Feb 2025; status: not yet recruiting.